Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · December 02, 2022

Efficacy and Safety of Q-122 for Treating Vasomotor Symptoms in Women With Breast Cancer Taking Tamoxifen or Aromatase Inhibitors

The Lancet


Additional Info

The Lancet
Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial
Lancet 2022 Nov 12;400(10364)1704-1711, A Vrselja, A Latifi, RJ Baber, BGA Stuckey, MG Walker, V Stearns, M Hickey, SR Davis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading